key: cord-0879291-4j4bdh0q authors: Ma, Shu‐Qing; Zhang, Jing; Wang, Yu‐Shan; Xia, Jun; Liu, Peng; Luo, Hong; Wang, Ming‐Yi title: Glucocorticoid therapy delays the clearance of SARS‐CoV‐2 RNA in an asymptomatic COVID‐19 patient date: 2020-05-29 journal: J Med Virol DOI: 10.1002/jmv.26086 sha: eefa1385922f065a8e29499195103e97878f9e32 doc_id: 879291 cord_uid: 4j4bdh0q The outbreak of severe acute respiratory syndrome‐related coronavirus 2 (SARS‐CoV‐2) started in Wuhan China, has become a global health concern. At present, glucocorticoid therapy is one of the most typically controversial treatments with COVID‐19 patients. Here, we reported an asymptomatic COVID‐19 patient with persistent positive detection of SARS‐CoV‐2 for 3 weeks and proposed that glucocorticoid therapy delays the clearance of SARS‐CoV‐2 RNA. Therefore, more attention must be paid to the COVID‐19 patients receiving glucocorticoid therapy. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. At present, twice successively negative detections of SARS-CoV-2 remain important index for discharged COVID-19 patients, and the median hospital stay is 10 days 6 . Here, we reported an asymptomatic COVID-19 patient with persistent positive detection of SARS-CoV-2 RNA for 3 weeks, and proposed that glucocorticoid therapy might not only cause atypical infections, but also delay the clearance of SARS-CoV-2 RNA. On January 24, a 48-year-old man with fever for 4 days was admitted to the hospital, and he had a history of short stay in Wuhan. Moreover, he had a 10-year history of asthma, and persistently received the inhaled glucocorticoids (salmeterol/fluticasone) at a dose of 50/250 μg twice daily. On admission, he developed low-grade fever and cough. CT images showed the increase of ground-glass opacity in the bilateral superior lobe. Nasopharyngeal swab sample was collected with the standard process as previously described 7 . RNA was extracted with the protease K-magnetic beads (BioPerfectus Technologies, China). From January 25 to January 28, he received efficient antiviral treatment, including oseltamivir, lopinavir/ritonavir and IFNα-2b. Considering the asthma attack, the patient felt chest tightness to receive the atomization budesonide and terbutaline from January 25. From January 28, he was treated with methylprednisolone to prevent the exacerbation. On January 31, he had the obvious improvement in respiratory symptoms. From February 1, he developed a wheeze and paroxysmal cough, and was administered with budesonide and terbutaline to reduce the airway A novel coronavirus from patients with pneumonia in China Controversial treatments: An update understanding of the coronavirus disease 2019 New coronavirus pneumonia prevention and control program National Health Commission of the People's Republic of China Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Detection and analysis of nucleic acid in various biological samples of COVID-19 patients Efficacy and safety of glycocorticoids in the treatment of severe community-acquired pneumonia: a meta-analysis Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection This article is protected by copyright. All rights reserved. Conflicts of interest: None to disclose.